NASDAQ:ELDN Eledon Pharmaceuticals Q2 2026 Earnings Results & Report $1.78 -0.12 (-6.32%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$1.79 +0.01 (+0.73%) As of 11/20/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Eledon Pharmaceuticals missed analyst earnings expectations in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.27 versus the -$0.1580 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeAfter Market ClosesConference Call4:00 PM ET Eledon Pharmaceuticals EPS ResultsActual EPS-$0.27Consensus EPS -$0.1580Beat/MissMissed by -$0.1120One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersEledon Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Eledon Pharmaceuticals Q2 2026 Earnings FAQ Did Eledon Pharmaceuticals beat earnings estimates for Q2 2026? Eledon Pharmaceuticals (NASDAQ:ELDN) reported earnings of -$0.27 per share for Q2 2026, missing the consensus estimate of -$0.1580. The report was announced on Thursday, August 13, 2026. Eledon Pharmaceuticals Earnings HeadlinesWhat is Noble Financial's Estimate for ELDN FY2026 Earnings?November 20 at 1:43 AM | americanbankingnews.comEledon Pharmaceuticals (NASDAQ:ELDN) Raised to Sell at Wall Street ZenNovember 14, 2026 | americanbankingnews.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 21 at 1:00 AM | Porter & Company (Ad)Eledon Pharmaceuticals Warns of Going-Concern Risk as Cash Shortfall Threatens R&D, Operations, and Shareholder ValueNovember 14, 2026 | tipranks.comEledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12, 2026 | marketscreener.comMEledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business HighlightsNovember 12, 2026 | globenewswire.comSee More Eledon Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email. Email Address About Eledon PharmaceuticalsEledon Pharmaceuticals (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company developing therapies for serious diseases involving the immune system. The company’s research focuses on modulating immune responses to help address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS). Its lead investigational product, tegoprubart, is an antibody that targets CD40 ligand, a protein involved in immune-system activation. Eledon is studying tegoprubart as a potential treatment to reduce rejection following organ transplantation and in research involving ALS. The therapy is experimental and has not been approved for commercial use. Eledon is headquartered in Irvine, California. The company’s work is focused on research and clinical development; it does not currently offer an approved commercial product.View Eledon Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in LimboAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity StocksHard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.